Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Related Articles
AACR Outstanding Investigator shares work on integrative breast cancer subtypes – SABCS Meeting News
Christina Curtis, PhD, MSc, on Wednesday discussed processes that drive cancer progression across various disease stages and molecular subtypes.
Revumenib Combo Yields High Remission Rates in Relapsed/Refractory AML
The combination of revumenib plus decitabine/cedazuridine showed high rates of remission among patients with relapsed/refractory AML with KMT2Ar, NPM1mt, and NUP98r genetic alterations.
Now’s the time to discuss family health history
Knowing your family health history is important — and could ultimately be life-saving for you or a family member. Kari Thorsen, MS, CGC, is a…
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer
This randomized clinical trial investigates whether a single oral dose of cannabidiol improves scan-related anxiety in women with advanced breast cancer.
Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium
A pooled analysis of 9548 HNC cases and 15,783 controls from the International Head and Neck Cancer Epidemiology consortium was conducted to assess the association…
Lurbinectedin Demonstrates Promise As Second-Line Option for Patients With Platinum-Sensitive Small Cell Lung Cancer
Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse…
Fox Chase Perioperative Care Team Enjoys a Lively Lunch to Celebrate the Season
Holiday happenings around Temple Health this year included a festive luncheon attended by members of the Perioperative Care team at Fox Chase Cancer Center.
Evaluating the Economic Impact of Novel Oncology Drug Coverage Through Patient Assistance Programs | JCO Oncology Practice
PURPOSEDespite a universal public health care system, Canadian oncology patients often enroll in patient assistance programs (PAPs) to access oncology drugs that are awaiting funding…
